… EST This presentation will highlight ProQR’s proprietary Axiomer ® platform, a fully owned and in house developed RNA … in the retina with oligonucleotide therapeutics. About Axiomer ® platform technology ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… to ProQR’s novel RNA editing platform technology called Axiomer LEIDEN, the Netherlands, May 09, 2017 (GLOBE … led to a novel proprietary RNA editing platform, called Axiomer, which in our view is the next step in RNA …
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome